ClinicalTrials.gg
Not yet recruitingNCT06049342NCR100Updated Jan 19, 2024

A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA

A Phase 1 interventional study of NCR100 injection in Knee Osteoarthritis, sponsored by Nuwacell Biotechnologies Co., Ltd.. Not yet recruiting. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-19.

Sponsored by Nuwacell Biotechnologies Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It is a dose-escalating, open label study in adult KOA subjects.

Read the detailed description

Knee osteoarthritis (KOA) is a kind of degenerative joint disease and there are over 300 million cases worldwide. The aim of this clinical trial is to evaluate the safety, tolerability, and efficacy of human pluripotent stem cell derived mesenchymal stromal cells (NCR100) injection in the treatment of subjects with knee osteoarthritis.

02

Conditions studied

  • Knee Osteoarthritis

Keywords

  • KOA
  • Mesenchymal Stromal Cells
03

In context

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 12 is below the median of 68 across 2,716 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Nuwacell Biotechnologies Co., Ltd. is the lead sponsor of 10 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who understand and voluntarily sign the Form(ICF) before the enrolment;
  • Age: 40-80 years old, both genders;
  • Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria;
  • Subjects with KOA who have persistent pain for more than six months, or aggravation or recurrence of osteoarthritis after routine medication;
  • Kellgren-Lawrence grade: II-III;
  • McMaster Universities Osteoarthritis Index (WOMAC): 24-72.

Exclusion criteria

Exclusion Criteria:

  • Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnosed with hip/ankle joint disease requiring medical intervention;
  • Subjects who suffering from other diseases that cause damage to knee joint function or affect joints;
  • Subjects who have received allogeneic mesenchymal progenitor (stem/stromal) cell therapy;
  • Subjects who have history of knee joint injury;
  • Subjects who have undergone knee arthroscopic surgery;
  • Subjects who received painkillers ( eg,opioids/nonsteroidal anti-inflammatory analgesics ) to treat knee osteoarthritis;
  • Subjects who have orally taken traditional Chinese medicine;
  • Subjects who have received intra-articular drug injection to treat knee osteoarthritis;
  • Subjects with glucosamine, chondroitin sulfate, or diacetate therapy before drug intervention
  • Subjects with acute reactive knee osteoarthritis;
  • Severe eversion deformity in target knee joint;
  • Known or suspected allergy or a history of allergies;
  • Subjects with abnormal results of laboratory examination: Hepatic Insufficiency ( > 2xULN or Aspartate aminotransferase(AST) > 2xULN), renal dysfunction ( rate ≤60ml/min or blood urea nitrogen(BUN) > 2× ), Coagulation Defects ( > 1.5) or severe hematological diseases (Grade 3 or above anemia \< 8 g/dL, Grade 2 or above thrombocytopenia count(PLT) \< 75×10\^9/L) ;
  • ≥30 kg/m\^2 ;
  • Severe systemic infection or local knee joint infection;
  • Subjects who have received systemic therapy before intervention or need to take systemic glucocorticoid therapy during the treatment;
  • Subjects who have history of acute myocardial infarction or with heart diseases e.g.uncontrolled angina pectoris, uncontrolled arrhythmias, severe heart failure ( > III), , and are determined by investigators as not suitable to participate in this clinical trial;
  • Subjects with peripheral or central nervous system disorders that may interfere with knee joint pain and functional assessment,
  • Subjects who have to MRI;
  • Subjects who have poor physical condition and are unable to walk autonomously;
  • Subjects with alcohol or drug addiction or with a clear history of mental disorders or with a history of drug abuse or drug use of psychotropic substances;
  • Subjects with infection with virus(HBV), virus(HCV), , and treponema pallidum confirmed by laboratory tests;
  • Pregnant or lactating female subjects, or subjects who are unable to comply with from the study period to 6 months after the end of this study;
  • Subjects who have participated in other clinical trials and have used other study products;
  • Subjects with severe and poorly controlled comorbidities and not suitable for this clinical trial;
  • Subjects who are not suitable for this clinical trial for other reasons.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    NCR100 injection

    Cohort1:Low dose NCR100 injection; Cohort2:Mid-low dose NCR100 injection; Cohort3:Mid-high dose NCR100 injection; Cohort4:High dose NCR100 injection.

    Biological: NCR100 injection

Interventions

  • Subjects will receive a one-dose intra-articular NCR100 injection.

06

What researchers measure

Primary outcomes

  1. Adverse Event(AE) or Serious Adverse Event(SAE)

    Number of participants with treatment-related adverse events or serious adverse events as assessed by CTCAE v5.0

    Time frame: Week1,Week2,Week4

  2. Dose-Limiting Toxicity(DLT)

    Number of participants with Dose-limiting toxicity in 28 days after injection

    Time frame: 4 weeks after injection

Secondary outcomes

  1. Maximum plasma concentration(Cmax)

    Time frame: 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration

  2. Elimination half life of drug(T1/2)

    Time frame: 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration

  3. Time after doing at which maximun plasma concentration is reached(Tmax)

    Time frame: 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration

  4. Area under the plasma concentration-time curve(AUC)

    Time frame: 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jun 2024, 5 months later.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's planned 5 months is below that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 22, 2023
StartEst.
Jan 25, 2024
Primary completionEst.
Jun 2024
CompletionEst.
May 2025
Last update
Jan 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049342
Lead sponsor
Nuwacell Biotechnologies Co., Ltd.
Collaborators
Shanghai 6th People's Hospital, Beijing Luhe Hospital
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Jan 25, 2024 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
May 2025 (estimated)
Last update
Jan 19, 2024

Study contacts

Xiaowen Gong
Contact
xwgong@nuwacell.com
15221195602
Changqing Zhang
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NCR100

Start the discussion